Welcome to ASCO Connection Discussion

The ASCO Connection Discussion forum is a space for oncology professionals and others with an interest in cancer care to ask and answer questions about every aspect of the field, from professional development advice to clinical conundrums. Everyone is welcome to participate: to ask a question or leave a response, first log in with your ASCO username and password. Please read the Discussion and Commenting Guidelines before you post a question or response. Contact our staff by email for assistance with the Discussion forum.

LOGIN TO START A DISCUSSION
Filter by All Topics
Research and Meeting News
Virginia D. Anderson
Jan 24, 2017 1:16 PM
The Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research is now accepting applications for its 2017 class of scholars. Sponsored by the Neurofibromatosis Therapeutic Acceleration Program at Johns Hopkins University, the Program works to create a community of...
Molecular Oncology Tumor Board
ASCO University
Jan 11, 2017 2:00 PM
Read more to answer the following questions: 1) Which tests are the most appropriate in identifying a BRAF codon 600 mutation for potential FDA-targeted treatment? 2) What is the significance of the CDKN2A mutation? 3) If systemic therapy is selected, would you be more inclined to offer targeted...
International
ASCO International Affairs
Dec 21, 2016 11:45 AM
ASCO recently partnered with local organizers to hold an International Palliative Care Workshop in China and a Cancer Control in Primary Care course in Brazil.
The IPCW was held in Luoyang in October in partnership with the 1st Affiliated Hospital of Henan University of Science and Technology. More...
Molecular Oncology Tumor Board
ASCO University
Dec 07, 2016 8:16 AM
Read more to answer the following questions:
Is further tissue needed to confirm radiologically presumed metastatic disease or for repeat HER2 testing? What systemic therapy option would you recommend for confirmed HER2 negative metastatic gastric cancer?
Molecular Oncology Tumor Board
ASCO University
Nov 09, 2016 11:09 AM
Read more to answer the following questions:

 Recognize the clinical characteristics and outcomes for patients with FLT3 mutations?
Describe the role of FLT3 inhibitors for the initial treatment of AML?
Understand the role of gene mutations, including CLT3,  in the pathologic classification of...

Pages